PO.TB10.07 · 肿瘤生物学

超越上皮-间充质转化的妇科癌肉瘤:肿瘤微环境中免疫梯度的形态-转录组学证据

Gynecologic carcinosarcomas beyond epithelial-mesenchymal transition: Morpho-transcriptomic evidence of an immune gradient in the tumor microenvironment

编号 6209 展板 23 时间 4/21 02:00–05:00 区域 Section 31 主讲 Amel Kime, MD;MS
分会场 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Amel Kime1, Julie Berthet1, Juliette Renard1, Antoine Gaudet Chardonnet2, Pierre Laurent-Puig1, Jerome Alexandre3, Bruno Borghese2, Guillaume Beinse3

1MEPPOT Team, Cordeliers Research Center, Paris, France,2Gynecologic Surgery Unit, APHP - Cochin Port-Royal Hospital, Paris, France,3Oncology Unit, APHP - Cochin Port-Royal Hospital, Paris, France

摘要 Abstract

中文摘要
引言:妇科癌肉瘤(GynCS)是罕见、侵袭性的子宫和卵巢癌,中位生存期不足两年。其生物学以上皮-间充质转化(EMT)为标志,驱动播散并形成双相性癌-肉瘤形态。然而,超越EMT之外的肿瘤内异质性分子驱动因素仍知之甚少。本研究旨在通过表征GynCS的转录组图景来阐明这些机制。 方法:一位妇科病理学家复阅了35例子宫和卵巢癌肉瘤的苏木精-伊红-藏红花(HES)切片。共选取251个肿瘤组织区域(包括癌、肉瘤和混合成分)进行形态学评估,并使用SMARTer文库制备试剂盒进行bulk RNA测序(RNA-seq)。 结果:在纳入队列的35个肿瘤中,33个(94%)为TP53突变型,2个(4%)无特定分子谱,1个(2%)为错配修复缺陷型,无一为POLE突变型。EMT表达特征与组织学特征相关,尽管26%组织学呈肉瘤样的区域根据RNAseq(WISP分类器)被重新分类为上皮型。将所有癌区域与所有肉瘤区域进行比较的基因集富集分析(GSEA)显示,除EMT外,炎症和免疫反应的耗竭是主要机制。RNA-seq数据的细胞类型去卷积以及FFPE切片上的免疫组化CD3染色均提示,与肉瘤区域相比,癌区域的肿瘤微环境中T细胞(尤其是细胞毒性T细胞)富集。在一部分肿瘤(n=15)中进行的瘤内免疫基因集分析揭示了患者间异质性的微环境转变,53%的肿瘤(n=8)从热微环境向冷微环境转变,而多数其余肿瘤(47%;n=7)则维持免疫缺乏状态。基因表达谱揭示了由cGAS-STING持续激活的非经典NFκB通路,可能是免疫耗竭的主要原因并与EMT相关。4个代表性病例的空间RNAseq(Visium2)证实炎症反应是空间变异性最强的特征之一。 结论:本研究提示,染色体不稳定通过cGAS-STING通路发挥双重作用,既驱动免疫耗竭又促进EMT成为关键生物学特征,尽管这一过程存在显著的肿瘤间变异。这些发现与关于非经典NFκB通路的现有文献一致。这项工作凸显了潜在的治疗机会,包括新兴的STING靶向治疗以及针对每个肿瘤独特免疫图景量身定制的个体化免疫治疗策略。
查看英文原文 English abstract
Introduction: Gynecologic carcinosarcomas (GynCS) are rare, aggressive uterine and ovarian cancers with a median survival under two years. Their biology is marked by epithelial-mesenchymal transition (EMT), driving dissemination and a biphasic carcinoma-sarcoma morphology. However, the molecular drivers of intratumoral heterogeneity beyond EMT remain poorly understood. This study seeks to clarify these mechanisms by characterizing the transcriptomic landscape of GynCS. Methods: Hematoxylin-eosin-saffron (HES) slides from 35 uterine and ovarian carcinosarcomas were reviewed by a gynecologic pathologist. A total of 251 tumoral tissue sectors, including carcinoma, sarcoma and mixed components, were selected for morphological assessment and bulk RNA sequencing (RNA-seq) using the SMARTer library preparation kit. Results: Among 35 tumors included in cohort, 33 (94%) were TP53-mutated, 2 (4%) had no specific molecular profile, 1 (2%) was mismatch repair-deficient and none was POLE-mutated. EMT expression signature correlated with histological features despite 26% of histologicaly sarcomatous sectors being reclassified as epithelial based on RNAseq (WISP classifier). Gene set enrichment analysis (GSEA) in all carcinoma sectors compared to all sarcoma sectors revealed a depletion in the response to inflammation and immunity as the main mechanism alongside EMT. Both cell-type deconvolution on RNA-seq data and immunohistochemical CD3 staining on FFPE slides suggest an enrichment in T cells, particularly cytotoxic T cells, in the tumor microenvironment of carcinoma sectors compared to sarcoma sectors. Within-tumor immune gene set analysis in a subset of tumors (n=15) revealed heterogeneous microenvironmental switch across patients, with 53% of tumors (n=8) shifting from a hot-to-cold microenvironment while most others (47%; n=7) remained immune-deprived. Gene expression profiles revealed the sustained activation of non-canonical NFκB pathway by cGAS-STING as a potentially leading cause of immune exhaustion and associated with EMT. Spatial RNAseq (Visium2) of 4 representative cases confirmed inflammation response as among most spatially variable features. Conclusion: This study suggests that chromosomal instability, acting through the cGAS-STING pathway, plays a dual role in driving immune exhaustion and promoting EMT as key biological features, despite notable inter-tumor variability in this process. These findings are consistent with existing literature on the non-canonical NFκB pathway. This work highlights potential therapeutic opportunities, including the emerging STING-targeted treatments and personalized immunotherapeutic strategies tailored to the unique immune landscape of each tumor.
利益披露 Disclosure
A. Kime, None.. J. Berthet, None.. J. Renard, None.. A. Gaudet Chardonnet, None.. P. Laurent-Puig, None.. J. Alexandre, None.. B. Borghese, None.. G. Beinse, None.

← 返回 AACR 2026 检索